BioClinica Launches Optimizer to Improve Clinical Trial Supply Planning
BIOCLINICA LAUNCHES OPTIMIZER TO IMPROVE CLINICAL TRIAL SUPPLY PLANNING
BioClinica™, Inc., (NASDAQ: BIOC), a global provider of clinical trial management services, today announced the launch of BioClinica Optimizer, a breakthrough for clinical supply planning and management that it believes has the potential to transform clinical trial supply forecasting and management. BioClinica Optimizer is a new product that combines and enhances the features of tcVisualize and tcOptimizer developed by Tourtellotte Solutions, which was acquired by BioClinica in September 2009. Allowing a customer to move beyond the current environment of spreadsheets and manual tools to plan and analyze clinical supply chains programmatically, BioClinica Optimizer integrates planning and feedback loops with other eClinical technologies.
“BioClinica now offers the premiere eClinical solution available to help our customers plan, forecast and optimize their clinical trials,” said Mark Weinstein, CEO of BioClinica, Inc. “Optimizer provides customers the ability to streamline this vital process, potentially saving them hundreds of thousands of dollars per trial.”
“As the complexity of clinical trials continues to increase, it is imperative that accurate clinical supply planning -- coupled with rigorous tracking -- be a standard part of the process,” said Ed Tourtellotte, VP of Product Innovation for BioClinica. “Many trials today are simply too complex and expensive to forecast without simulation. Though savings in materials and logistics can be substantial, the real win is to foresee and prevent stock-outs. Running out of critical supplies requires emergency shipments or catastrophically can even risk an entire trial, potentially costing both time and millions of dollars. Based upon the successes that our customers have had thus far, we can say with confidence that our new Optimizer product provides the optimal supply forecasting solution.”
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
